Drugs / 18F-AlF-NOTA-octreotide
18F-AlF-NOTA-octreotide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03511768 | Jan 2018 → Dec 2019 | neuroendocrine neoplasm | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-AlF-NOTA-octreotide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03511768 ↗ |
| Modality | Diagnostic / imaging agent | “The radioligand can be used for the diagnosis and stage of the NENs.” NCT03511768 ↗ |